We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+12.94%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.11B
AUM Growth
+$673M
(+20%)
Cap. Flow
-$283M
Cap. Flow
% of AUM
-6.89%
Top 10 Holdings %
Top 10 Hldgs %
37.55%
Holding
125
New
30
Increased
16
Reduced
24
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AFIB
Acutus Medical Inc
AFIB
|
+$132M |
| 2 |
CalciMedica
CALC
|
+$78.7M |
| 3 |
Nkarta
NKTX
|
+$71.3M |
| 4 |
Centene
CNC
|
+$58.5M |
| 5 |
OSH
Oak Street Health, Inc.
OSH
|
+$42.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schrodinger
SDGR
|
+$123M |
| 2 |
HOLX
Hologic
HOLX
|
+$62.2M |
| 3 |
McKesson
MCK
|
+$42.7M |
| 4 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$31.2M |
| 5 |
Pacira BioSciences
PCRX
|
+$27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.18% |
| 2 | Financials | 1.23% |
| 3 | Industrials | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Spyre Therapeutics
SYRE
$8.68B
| – | – |
-33,000
| Closed | -$7.63M |
|
102
Xeris Biopharma Holdings
XERS
$1.42B
| – | – |
-3,178,551
| Closed | -$8.46M |
|
|
SILK
103
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| – | – |
-744,998
| Closed | -$31.2M |
|
|
MRTX
104
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-179,885
| Closed | -$20.5M |
|
|
VAPO
105
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| – | – |
-64,646
| Closed | -$21.2M |
|
|
CSII
106
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-650,000
| Closed | -$20.5M |
|
|
AKUS
107
DELISTED
Akouos Inc
AKUS
| – | – |
-318,034
| Closed | -$7.16M |
|
|
TPTX
108
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| – | – |
-188,490
| Closed | -$12.2M |
|
|
AVEO
109
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| – | – |
-357,101
| Closed | -$1.84M |
|
|
ELGX
110
DELISTED
Endologix Inc
ELGX
| – | – |
-950,000
| Closed | -$764K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q3 2020 Portfolio in Review
As of Q3 2020, Deerfield Management held 125 positions worth $4.11B, up 20% from $3.43B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Deerfield Management withdrew a net $283M in Q3 2020, closing 24 positions and reducing 24 holdings. Its most notable exit was Schrodinger, an estimated $123M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 66% a quarter earlier, followed by Financials and Industrials.
Against the trend, Deerfield Management opened a new position in Acutus Medical Inc worth $129M.
- Deerfield Management's largest Q3 2020 buy was Acutus Medical Inc: 4,341,799 shares worth $129M.
- Deerfield Management added most to Centene in Q3 2020, an estimated $58.5M increase.
- Deerfield Management's biggest Q3 2020 reduction was Hologic, cutting an estimated $62.2M.
- Deerfield Management fully exited Schrodinger in Q3 2020, selling an estimated $123M.
- Deerfield Management's ten largest holdings make up 38% of its $4.11B portfolio in Q3 2020.
- Deerfield Management opened 30 new positions and closed 24 in Q3 2020.
- Deerfield Management's portfolio value rose 20% quarter-over-quarter to $4.11B.
Based on Deerfield Management's 13F filing for Q3 2020, filed 16 Nov 2020.